SCHEMBL4891070

SCHEMBL4891070

CC(C)(C)c1ccc2c(c1)N(C(=O)c1cc(Cl)c(O)c(Cl)c1)CCO2

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 5/20 0.47
SLC22A6 Q4U2R8 1/20 0.47
SLC22A8 Q8TCC7 1/20 0.47
POLB P06746 5/20 0.46
ALDH1A1 P00352 1/20 0.41
TP53 P04637 4/20 0.40
MAPT P10636 4/20 0.40
THRB P10828 1/20 0.40
CYP2C9 P11712 1/20 0.40
ABCG2 Q9UNQ0 1/20 0.40
NR3C2 P08235 1/20 0.39
RXFP1 Q9HBX9 2/20 0.39
IDO1 P14902 1/20 0.38
KCNH2 Q12809 1/20 0.38
NOTUM Q6P988 1/20 0.38
GAA P10253 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4901585 0.89 SLC22A12 (0.47) SLC22A12SLC22A6SLC22A8POLBTP53
SCHEMBL4892147 0.85 MAPT (0.50) SLC22A12SLC22A6SLC22A8POLBALDH1A1
SCHEMBL4902073 0.84 POLB (0.51) SLC22A12SLC22A6SLC22A8POLBTP53
SCHEMBL4892266 0.84 POLB (0.57) SLC22A12SLC22A6SLC22A8POLBTP53
SCHEMBL4901883 0.82 SLC22A12 (0.49) SLC22A12SLC22A6SLC22A8POLBTP53
SCHEMBL4903934 0.82 POLB (0.52) SLC22A12SLC22A6SLC22A8POLBALDH1A1
SCHEMBL4895663 0.82 SLC22A12 (0.49) SLC22A12SLC22A6SLC22A8POLBTP53
SCHEMBL4898938 0.82 THRB (0.54) SLC22A12SLC22A6SLC22A8POLBALDH1A1
SCHEMBL4890179 0.81 CYP2C9 (0.50) SLC22A12SLC22A6SLC22A8POLBALDH1A1
SCHEMBL4901855 0.81 POLB (0.70) SLC22A12SLC22A6SLC22A8POLBTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080064871-A1 Production Method of Nitrogen-Containing Fused Ring Compounds JAPAN TOBACCO INC. (JP) 2008-03-13 US claimed
EP-1820515-A1 NITROGEN-CONTAINING FUSED RING COMPOUND AND USE THEREOF Japan Tobacco, Inc. (JP) 2007-08-22 EP claimed
US-20070010670-A1 Nitrogen-containing fused ring compounds and use thereof JAPAN TOBACCO INC. (JP) 2007-01-11 US claimed
US-20080305169-A1 Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds JAPAN TOBACCO INC. (JP) 2008-12-11 US disclosed
US-20080305169-A1 Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds JAPAN TOBACCO INC. (JP) 2008-12-11 US disclosed
US-20080305169-A1 Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds JAPAN TOBACCO INC. (JP) 2008-12-11 US disclosed
US-20080064871-A1 Production Method of Nitrogen-Containing Fused Ring Compounds JAPAN TOBACCO INC. (JP) 2008-03-13 US disclosed
US-20080064871-A1 Production Method of Nitrogen-Containing Fused Ring Compounds JAPAN TOBACCO INC. (JP) 2008-03-13 US disclosed
US-20080064871-A1 Production Method of Nitrogen-Containing Fused Ring Compounds JAPAN TOBACCO INC. (JP) 2008-03-13 US disclosed
EP-1820515-A1 NITROGEN-CONTAINING FUSED RING COMPOUND AND USE THEREOF Japan Tobacco, Inc. (JP) 2007-08-22 EP disclosed
US-20070010670-A1 Nitrogen-containing fused ring compounds and use thereof JAPAN TOBACCO INC. (JP) 2007-01-11 US disclosed
US-20070010670-A1 Nitrogen-containing fused ring compounds and use thereof JAPAN TOBACCO INC. (JP) 2007-01-11 US disclosed
US-20070010670-A1 Nitrogen-containing fused ring compounds and use thereof JAPAN TOBACCO INC. (JP) 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080305169-A1 Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds NOD1, NLRP3, SLC10A1 SLC22A12 446/4885SLC22A6 521/4885SLC22A8 216/4885
US-20070010670-A1 Nitrogen-containing fused ring compounds and use thereof NUDT1, NOD1, SLC28A1 SLC22A12 260/4885SLC22A6 375/4885SLC22A8 222/4885
US-20080064871-A1 Production Method of Nitrogen-Containing Fused Ring Compounds NOD1, XDH, URB2 SLC22A12 371/4885SLC22A6 285/4885SLC22A8 354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.